MELBOURNE, AUSTRALIA 4 November 2026: Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell therapy platform, provides the Chair’s address and the CEO’s presentation for today’s Annual General Meeting.
The meeting commences at 11:00am AEDT held virtually via an online platform. Full details of the meeting can be found in the Notice of Annual General Meeting dated 5 October 2026.
